NEUROONE MEDICAL TECHNOLOGIES Corp 8-K

What Happened
On May 21, 2026 the Audit Committee of NeuroOne Medical Technologies determined that the company’s interim financial statements in its Form 10‑Q for the quarter ended March 31, 2026 (filed May 12, 2026) should no longer be relied upon and will be restated due to accounting errors related to revenue recognition. The company issued a press release on May 22, 2026 announcing the planned restatement. Management says the errors were partly caused by inadequate design and implementation of internal controls around evaluation of certain customer modified purchase orders. The company will amend the Previous Filing, restate the unaudited condensed financial statements and amend MD&A; the amounts disclosed are preliminary and may change as the review proceeds. The company states these matters did not involve intentional misconduct.

Key Details

• Audit Committee determination date: May 21, 2026; press release dated May 22, 2026; original 10‑Q filed May 12, 2026.
• Revenue and accounts receivable were overstated by an estimated $529,000 for the three‑ and six‑month periods ended March 31, 2026.
• Gross profit was overstated by an estimated $296,000; operating loss and net loss were understated by an estimated $296,000 for the same periods.
• As of March 31, 2026 the company estimates total assets were overstated by $296,000 and inventory was understated by $233,000.

Why It Matters
A restatement means the company’s recently reported quarterly results and related communications are unreliable until revised. That affects how investors should interpret NeuroOne’s reported revenue, gross profit and losses for Q1 2026 and any metrics or trend analyses that used the Previous Filing. The company cites internal control deficiencies (not intentional misconduct) and is conducting a review; numbers are preliminary and could change when the amended 10‑Q is filed. Investors should watch for the amended filing and any further disclosures about control fixes or auditor findings.